

Tablica 10. Prvih 30 lijekova po financijskoj potrošnji u eurima, BOLNIČKA
POTROŠNJA u 2024. godini

RBR	ATK	INN	UKUPNI IZNOS EUR
1	L01FF02	pembrolizumab	94.975.708
2	L02BB04	enzalutamid	24.407.074
3	L01EL01	ibrutinib	20.622.250
4	L01FF01	nivolumab	20.539.652
5	L01FG01	bevacizumab	20.084.303
6	L01FC01	daratumumab	19.023.586
7	L01FF05	atezolizumab	18.582.657
8	L04AA36	okrelizumab	18.026.758
9	J06BA02	imunoglobulini, humani, za i.v. primjenu	17.148.291
10	L01FD02	pertuzumab	14.969.478
11	L04AX04	lenalidomid	13.106.947
12	R07AX32	ivakaftor, tezakaftor i eleksakaftor	13.038.349
13	L01XX52	venetoklaks	12.385.750
14	L01FY01	pertuzumab i trastuzumab	12.116.015
15	L04AB02	infliksimab	11.223.508
16	M09AX10	risdiplam	10.791.297
17	L01EF03	abemaciclib	10.760.112
18	B05AA01	albumin, ljudski	10.478.844
19	B05BB01	elektroliti	10.329.803
20	L03AA13	pegfilgrastim	9.957.073
21	L01FD01	trastuzumab	9.846.772
22	L01EF02	ribociklib	9.525.667
23	R07AX02	ivakaftor	8.767.606
24	L01EF01	palbociklib	8.359.226
25	L02BB05	apalutamid	8.179.689
26	L01EL02	akalabrutinib	7.834.268
27	L01FA01	rituksimab	7.789.208
28	L01FX04	ipilimumab	7.582.944
29	L02BX03	abirateron	7.056.581
30	L04AA43	ravulizumab	6.749.961